id="n_292">292
Pihet M, Carrere J, Cimon B, et al. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis – a review. Med Mycol 2009; 47: 387-97
293
Le Bourgeois M, Sermet I, Bailly-Botuha C, et al. [Fungal infections in cystic fibrosis]. Arch Pediatr 2011; 18(Suppl1):S15-21.
294
Muller FM, Seidler M. Characteristics of pathogenic fungi and antifungal therapy in cystic fibrosis. Expert Rev Anti Infect Ther 2010; 8: 957-64.
295
Nielsen SM, Kristensen L, S0ndergaard A, et al. Increased prevalence and altered species composition of filamentous fungi in respiratory specimens from cystic fibrosis patients. APMIS 2014; 122: 1007-12.
296
Skov M. Aspergillus fumigatus lung colonization and infection in patients with cystic fibrosis. PhD thesis. University of Copenhagen, Denmark. 2001.
297
Shoseyov D, Brownlee KG, Conway SR et al. Aspergillus bronchitis in cystic fibrosis. Chest 2006; 130: 222-6.
298
Jones AM, Horsley A, Denning DW. What is the importance of classifying Aspergillus disease in cystic fibrosis patients? Expert Rev Respir Med 2014; 8: 389-92.
299
Shoseyov D, Brownlee KG, Conway SR et al. Aspergillus bronchitis in cystic fibrosis. Chest 2006; 130: 222-6.
300
Stevens DA, Moss RB, Kurup VR et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis – state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37(Suppl 3): S225-64.
301
Shoseyov D, Brownlee KG, Conway SR et al. Aspergillus bronchitis in cystic fibrosis. Chest 2006; 130: 222-6.
302
Meersseman W, Lagrou K, Maertens J, et al. Galactomannan in bronchoal-veolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 2008; 177:27–34.
303
Desai R, Ross LA, Hoffman JA. The role of bronchoalveolar lavage galactomannan in the diagnosis of pediatric invasive aspergillosis. Pediatr Infect Dis J 2009; 28: 283-6.
304
Denning DW. Chronic forms of pulmonary aspergillosis. Clin Microbiol Infect 2001; 7(Suppl 2): 25–31.
305
Kroner C, Kappler M, Grimmelt AC, et al. The basidiomycetous yeast Trlchosporon may cause severe lung exacerbation in cystic fibrosis patients – clinical analysis of Trlchosporon positive patients in a Munich cohort. BMC Pulm Med 2013; 13:61.
306
Kondori N, Lindblad A, Welinder-Olsson C, et al. Development of IgG antibodies to Exophiala dermatltldls is associated with inflammatory responses in patients with cystic fibrosis. J Cyst Fibros 2014; 13:391-9.
307
Parize P Billaud S, Bienvenu AL, et al. Impact of Scedosporium aplospermum complex seroprevalence in patients with cystic fibrosis. J Cyst Fibros 2014; 13: 667-73.
308
Holle J, Leichsenring M, Meissner PE. Nebulized voriconazole in infections with Scedosporium aplospermum – case report and review of the literature. J Cyst Fibros 2014; 13:400–402.
309
Russell GK, Gadhok R, Simmonds NJ. The destructive combination of Scediosporium apiosperum [sic] lung disease and exuberant inflammation in cystic fibrosis. Paediatr Respir Rev 2013; 14(Suppl 1): 22–25.
310
Muller FM, Seidler M. Characteristics of pathogenic fungi and antifungal therapy in cystic fibrosis. Expert Rev Anti Infect Ther 2010; 8: 957-64.
311
Chotirmall SH, Greene CM, McEIvaney NG. Candida species in cystic fibrosis: a road less travelled. Med Mycol 2010; 48(Suppl 1): S114-24.
312
Baxter CG, Moore CB, Jones AM, et al. IgE-mediated immune responses and airway detection of Aspergillus and Candida in adult cystic fibrosis. Chest 2013; 143: 1351-7.
313
Chamnan R Shine BS, Haworth CS, et al. Diabetes as a determinant of mortality in cystic fibrosis. Diabetes Care 2010; 33: 311-16.
314
Moran A, Dunitz J, Nathan B, et al. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care 2009; 32: 1626-31.
315
van den Berg JM, Kouwenberg JM, Heijerman HG. Demographics of glucose metabolism in cystic fibrosis. J Cyst Fibros 2009; 8: 276-9.
316
Lanng S, Hansen A, Thorsteinsson B, et al. Glucose tolerance in patients with cystic fibrosis: five year prospective study. BMJ 1995;311:655-9.
317
AdlerAI, Gunn E, Haworth CS, et al. Characteristics of adults with and without cystic fibrosis-related diabetes. Diabet Med 2007; 24: 1143-8.
318
Adler Al, Shine BS, Chamnan P, et al. Genetic determinants and epidemiology of cystic fibrosis-related diabetes: results from a British cohort of children and adults. Diabetes Care 2008; 31: 1789-94.
319
Adler Al, Shine BS, Chamnan P, et al. Genetic determinants and epidemiology of cystic fibrosis-related diabetes: results from a British cohort of children and adults. Diabetes Care 2008; 31: 1789-94.
320
Marshall ВС, Butler SM, Stoddard M, et al. Epidemiology of cystic fibrosis-related diabetes. J Pediatr 2005; 146: 681-7.
